Jignesh S Kotecha
☆    

India,
2019-05-12 18:53

Posting: # 20280
Views: 193
 

 Abridged application for modified release forms [Regulatives / Guidelines]

We are developing a prolonged release tablet for Europe market. This product has got single strength. The therapeutic doses is achieved with this single strength by increasing the number of tablets per day in three divided doses. These doses should be attained slowly, by step-wise increase by one tablet every two weeks.

We are required to conduct a single dose fasting, single dose fed and multiple dose study in fed condition. Since this product has single strength and dose is increased to therapeutic level step-wise, can we conduct the multiple dose study at given strength considering it as a sensitive strength?


Edit: Please follow the Forum’s Policy[Helmut]
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,486 posts in 4,135 threads, 1,334 registered users;
online 14 (0 registered, 14 guests [including 11 identified bots]).
Forum time (Europe/Vienna): 02:57 CEST

If debugging is the process of removing bugs,
then programming must be the process of putting them in.    Edsger W. Dijkstra

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5